# Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder

> **NCT00300378** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 480 (estimated)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** desvenlafaxine 50 mg
- **DRUG:** desvenlafaxine 100 mg

## Key facts

- **NCT ID:** NCT00300378
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2007-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00300378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00300378, "Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00300378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*